15 Best Biotech Stocks to Buy According to Billionaires
Although biotech stocks had a "challenging" year in 2024, JPMorgan believes that some of the industry's companies could see significant growth in the months to come.
Madrigal Pharmaceuticals Inc. (MDGL)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Armistice Capital Steven Boyd | 0 | $0 | 0% | |
| 2. | Millennium Management Israel Englander | 0 | $0 | 0% | |
| 3. | Citadel Investment Group Ken Griffin | 0 | $0 | 0% | |
| 4. | Baker Bros. Advisors Julian Baker And Felix Baker | 0 | $0 | 0% | |
| 5. | Renaissance Technologies Jim Simons | 0 | $0 | 0% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $229.86 | 3,960 | Director | 1,793,403 | 2023-12-14 | Filing | |
| $229.86 | 316 | Director | 185,979 | 2023-12-14 | Filing | |
| $228.79 | 2,204 | Director | 1,789,443 | 2023-12-14 | Filing | |
| $228.79 | 176 | Director | 185,663 | 2023-12-14 | Filing | |
| $227.86 | 11,602 | Director | 1,787,239 | 2023-12-14 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $330.23 | 75 | Director | 350,076 | 2025-03-13 | Filing | |
| $329.86 | 967 | Director | 350,151 | 2025-03-13 | Filing | |
| $328.68 | 400 | Director | 351,118 | 2025-03-13 | Filing | |
| $327.63 | 1,000 | Director | 351,518 | 2025-03-13 | Filing | |
| $325.63 | 800 | Director | 352,518 | 2025-03-13 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 0 | $0 | 0% | |
| 2. | 0 | $0 | 0% | |
| 3. | 0 | $0 | 0% | |
| 4. | 0 | $0 | 0% | |
| 5. | 0 | $0 | 0% |
News See All
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q4 2024 Earnings Call Transcript
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q4 2024 Earnings Call Transcript February 26, 2025Madrigal Pharmaceuticals, Inc. beats earnings expectations.
10 Worst Performing Biotech Stocks in 2024
Biotechnology stocks are among the most volatile in the market due to their high risk.
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q3 2024 Earnings Call Transcript
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q3 2024 Earnings Call Transcript October 31, 2024Madrigal Pharmaceuticals, Inc. beats earnings expectations.
10 Biggest Stocks with Negative Beta to Consider
Beta is a measurement of market risk or volatility that indicates how much the price of a stock tends to fluctuate up and down compared to other stocks.
10 Best Guru Stocks To Buy Now
Due to the plethora of investment options such as equities, bonds, and mutual funds that are available today, picking the right set of vehicles to either preserve or grow money can often seem to be a ...
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q2 2024 Earnings Call Transcript
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q2 2024 Earnings Call Transcript August 7, 2024Madrigal Pharmaceuticals, Inc. beats earnings expectations.
Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Q1 2024 Earnings Call Transcript
Madrigal Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-7.38 EPS, expectations were $-6.06.
Latest Insider Selling in April 2024: 10 Stocks to Watch
In this article, we will take a detailed look at Latest Insider Selling in April 2024: 10 Stocks to Watch. For a quick overview of the 5 such stocks, read our article Latest Insider Selling in April...
30 Biggest Biotechnology Companies in the World
In this article, we will be taking a look at the 30 biggest biotechnology companies in the world.
Billionaire Hedge Funds
